NEOS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NEOS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Neos Therapeutics's annualized Net Income for the quarter that ended in Sep. 2020 was $-19.64 Mil. Neos Therapeutics's average total tangible assets for the quarter that ended in Sep. 2020 was $52.25 Mil. Therefore, Neos Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2020 was -37.60%.
The historical rank and industry rank for Neos Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:
During the past 7 years, Neos Therapeutics's highest Return-on-Tangible-Asset was -19.56%. The lowest was -100.31%. And the median was -68.83%.
The historical data trend for Neos Therapeutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neos Therapeutics Annual Data | ||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||
Return-on-Tangible-Asset | Get a 7-Day Free Trial | -47.05 | -98.32 | -87.55 | -56.02 | -19.31 |
Neos Therapeutics Quarterly Data | ||||||||||||||||||||
Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | |
Return-on-Tangible-Asset | Get a 7-Day Free Trial | -10.64 | -17.78 | -40.96 | -34.44 | -37.60 |
For the Drug Manufacturers - Specialty & Generic subindustry, Neos Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Neos Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Neos Therapeutics's Return-on-Tangible-Asset falls into.
Neos Therapeutics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2019 is calculated as:
Return-on-Tangible-Asset | = | Net Income | / | ( (Total Tangible Assets | + | Total Tangible Assets) | / count ) |
(A: Dec. 2019 ) | (A: Dec. 2018 ) | (A: Dec. 2019 ) | |||||
= | Net Income | / | ( (Total Assets - Intangible Assets | + | Total Assets - Intangible Assets) | / count ) | |
(A: Dec. 2019 ) | (A: Dec. 2018 ) | (A: Dec. 2019 ) | |||||
= | -16.902 | / | ( (96.741 | + | 78.33) | / 2 ) | |
= | -16.902 | / | 87.5355 | ||||
= | -19.31 % |
Neos Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2020 is calculated as:
Return-on-Tangible-Asset | = | Net Income | / | ( (Total Tangible Assets | + | Total Tangible Assets) | / count ) |
(Q: Sep. 2020 ) | (Q: Jun. 2020 ) | (Q: Sep. 2020 ) | |||||
= | Net Income | / | ( (Total Assets - Intangible Assets | + | Total Assets - Intangible Assets) | / count ) | |
(Q: Sep. 2020 ) | (Q: Jun. 2020 ) | (Q: Sep. 2020 ) | |||||
= | -19.644 | / | ( (50.981 | + | 53.51) | / 2 ) | |
= | -19.644 | / | 52.2455 | ||||
= | -37.60 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2020) net income data.
Neos Therapeutics (NAS:NEOS) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Thank you for viewing the detailed overview of Neos Therapeutics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Alan L Heller | director | BAXTER INTERNATIONAL INC ONE BAXTER PKWY DF2-2W DEERFIELD IL 60015 |
Gregory J Robitaille | director | |
John P. Schmid | director | 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Beth Hecht | director | C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050 |
Linda M Szyper | director | C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050 |
Bryant Fong | director | 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123 |
Robinson James A. Jr. | director | 852 WINTER STREET, WALTHAM MA 02451 |
Gerald W. Mclaughlin | director, officer: Chief Executive Officer | 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428 |
Richard I Eisenstadt | officer: Chief Financial Officer | 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
John M Limongelli | officer: SVP & General Counsel | 700 PENNSYLVANIA DRIVE, EXTON PA 19341 |
Thomas P Mcdonnell | officer: Chief Commercial Officer | C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050 |
Vipin K Garg | officer: Chief Executive Officer | 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
Dorothy Engelking | officer: VP, Regulatory Affairs | C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050 |
Paul R Edick | director | C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010 |
Juergen Martens | officer: Chief Tech/Operations Officer | 28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
From GuruFocus
By Marketwired Marketwired • 12-11-2020
By Marketwired Marketwired • 11-02-2020
By Marketwired Marketwired • 03-11-2021
By Marketwired Marketwired • 12-10-2020
By Business Wire Business Wire • 12-10-2020
By Marketwired Marketwired • 11-01-2019
By Marketwired Marketwired • 05-26-2020
By Marketwired Marketwired • 02-26-2020
By Marketwired Marketwired • 02-10-2021
By Marketwired Marketwired • 09-25-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.